We analyzed the ERG gene status using fluorescence in situ hybridization (FISH) in two chemotherapynaïve cases with metastatic castration-resistant prostate cancer (mCRPC) in which abiraterone demonstrated a long-term durable complete response. FISH identified Class 1 Edel and Class 2+ Edel in case 1, and Class 1 Edel in case 2. Our experience suggests that abiraterone may be effective in cases with mCRPC and ERG gene abnormalities, particularly Class 2+ Edel or Class 1 Edel. This is the first report of two cases with mCRPC that simultaneously investigated the ERG gene status and clinical aspects, including image evaluations and pathology.
CITATION STYLE
Yoshizawa, T., Yamaguchi, K., Kawata, N., Ryuzaki, H., Ogawa, M., Obinata, D., … Takahashi, S. (2020). An ERG gene analysis in two cases with metastatic castration-resistant prostate cancer in which abiraterone demonstrated long-term efficacy. Internal Medicine, 59(3), 395–399. https://doi.org/10.2169/internalmedicine.3302-19
Mendeley helps you to discover research relevant for your work.